WO2018227749A1 - Nutriment for type 2 diabetes patient - Google Patents
Nutriment for type 2 diabetes patient Download PDFInfo
- Publication number
- WO2018227749A1 WO2018227749A1 PCT/CN2017/097584 CN2017097584W WO2018227749A1 WO 2018227749 A1 WO2018227749 A1 WO 2018227749A1 CN 2017097584 W CN2017097584 W CN 2017097584W WO 2018227749 A1 WO2018227749 A1 WO 2018227749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- type
- probiotics
- fruit
- metformin
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 22
- 239000006041 probiotic Substances 0.000 claims abstract description 22
- 235000018291 probiotics Nutrition 0.000 claims abstract description 22
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 19
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 19
- 239000000835 fiber Substances 0.000 claims abstract description 19
- 235000012055 fruits and vegetables Nutrition 0.000 claims abstract description 19
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 19
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 16
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 16
- 229920001503 Glucan Polymers 0.000 claims abstract description 9
- 244000302512 Momordica charantia Species 0.000 claims description 15
- 229920002307 Dextran Polymers 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 235000009815 Momordica Nutrition 0.000 claims description 5
- 241000218984 Momordica Species 0.000 claims description 5
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 description 20
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 208000024330 bloating Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000000110 microvilli Anatomy 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003538 oral antidiabetic agent Substances 0.000 description 3
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 235000021542 oral nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Type II diabetes accounts for more than 90% of diabetic patients. In patients with type 2 diabetes, the ability to produce insulin is not completely lost, and some patients may even produce insulin. Too much, but the effect of insulin is poor, so insulin in patients is a relatively lacking, can stimulate the secretion of insulin in the body through some oral drugs.
- Metformin is a biguanide oral hypoglycemic agent, which is the most commonly used oral hypoglycemic agent in clinical use.
- One of the first-line oral hypoglycemic drugs is used in patients with type 2 diabetes who are not satisfied with simple diet control, especially those with obesity and hyperinsulinemia.
- Metformin main pass Intestinal intake increase insulin sensitivity, increase the utilization of peripheral glucose, and inhibit excessive gluconeogenesis of liver and kidney, and not reduce blood sugar levels in non-diabetic patients.
- metformin mainly include digestive tract reactions such as diarrhea, nausea, vomiting, bloating, and bad breath. Most of them are prone to insulin resistance and have reduced efficacy. They are often combined with various oral hypoglycemic agents. It will also cause drug-type damage to the liver and kidneys.
- the technical solution adopted by the present invention is:
- a nutrient for type II diabetes patients which comprises the following components: fruit and vegetable fiber, prebiotics, oat glucan, blueberry extract, bitter gourd extract and probiotics.
- the mechanism of action and synergistic mechanism of each component can be offset by the balance of fruit and vegetable fiber, prebiotics, oat glucan, blueberry extract, bitter gourd extract and probiotics to regulate the intestinal flora of human body.
- the digestive tract reaction caused by metformin, nausea, vomiting, bloating and oral odor solves the technical problem of the side effects of metformin in patients with type 2 diabetes.
- it can also increase the efficacy of metformin, increase the ability of metformin to resist insulin resistance, and gradually reduce the dose of oral metformin.
- a nutritional supplement for type II diabetes patients comprising the following components: fruit and vegetable fiber, prebiotics, oat dextran, blueberry extract, bitter gourd extract and probiotics.
- the proportions of fruit and vegetable fiber, prebiotics, oat dextran, blueberry extract, bitter gourd extract and probiotics are:
- the nutritional product of the invention is mainly applied to the auxiliary treatment of type II diabetes, which can counteract the digestive tract reaction caused by metformin caused by diarrhea, nausea, vomiting, bloating and oral odor by regulating the balance of human intestinal flora, and can also increase The efficacy of metformin, which increases the ability of metformin to resist insulin resistance, can gradually reduce the dose of oral metformin.
- the medical nutrition product of the invention regulates the balance of the human intestinal flora by
- fruit and vegetable fiber and prebiotics can jointly promote the proliferation of probiotics (including lactobacilli and bifidobacteria), creating an environment in which the number of probiotics increases rapidly. Therefore, increasing the proportion of probiotics/pathogenic bacteria can directly improve side effects such as diarrhea, nausea, vomiting, and bloating caused by metformin.
- probiotics including lactobacilli and bifidobacteria
- Blueberry extract is a natural antioxidant as long as it acts through anthocyanins.
- Anthocyanins contain a plurality of phenolic hydroxyl groups, which are oxidized in the body to release H+, competitively bind to free radicals and oxides, thereby protecting lipids from oxidation and blocking free radical chain reactions. Reduces the side effects of metformin by effectively removing harmful free radicals from the gut.
- the bitter gourd extract acts only through the bitter gourd saponin, and the bitter gourd saponin acts mainly on the intestinal brush border.
- ⁇ -glucosidase By affecting ⁇ -glucosidase, it is present in the proximal epithelial cells of the brush border membrane of the small intestine, and its main function is to degrade starch, dextrin, maltose and sucrose into monosaccharides.
- Alpha-glycosidase inhibitors are currently the most studied oral hypoglycemic drugs for diabetes. They have a high affinity for glucosidase and act on the brush border of the small intestine mucosa, which can delay the digestion and absorption of carbohydrates in the intestine. It inhibits the increase of postprandial blood glucose levels, while at the same time reducing the fasting blood glucose to a certain extent.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a nutriment for a type II diabetes patient, comprising the following components: fruit and vegetable fibre, prebiotics, oat glucan, a blueberry extract, a bitter gourd extract and probiotics.
Description
技术领域 Technical field
本发明涉及一种II型糖尿病患者用营养品。The invention relates to a nutritional product for type II diabetes patients.
背景技术Background technique
中国约有1.1亿名糖尿病患者，约占中国成年人总数的1/10。若不尽快采取行动
，减少不健康饮食和缺乏运动等生活方式中的危险因素，预计该数字将在2040年增至1.5亿人，给民众健康和社会经济带来严
重影响。其中II型糖尿病占糖尿病患者90%以上。II型糖尿病患者体内产生胰岛素的能力并非完全丧失，有的患者体内胰岛素甚至产生
过多，但胰岛素的作用效果较差，因此患者体内的胰岛素是一种相对缺乏，可以通过某些口服药物刺激体内胰岛素的分泌。There are about 110 million people with diabetes in China, accounting for about one-tenth of the total number of Chinese adults. If not take action as soon as possible
To reduce risk factors in lifestyles such as unhealthy diets and lack of exercise, the number is expected to increase to 150 million in 2040, bringing health to the public and the economy.
Heavy impact. Type II diabetes accounts for more than 90% of diabetic patients. In patients with type 2 diabetes, the ability to produce insulin is not completely lost, and some patients may even produce insulin.
Too much, but the effect of insulin is poor, so insulin in patients is a relatively lacking, can stimulate the secretion of insulin in the body through some oral drugs.
二甲双胍是一种双胍类口服降血糖药,为目前临床使用最为普遍的口服降血糖药
物之一，是目前一线核心的口服降糖药物，用于单纯饮食控制不满意的II型糖尿病病人，尤其是肥胖和伴高胰岛素血症者。二甲双胍主要通
过肠道的摄取，提高胰岛素敏感性而增加外周葡萄糖的利用，以及抑制肝、肾过度的糖原异生，不降低非糖尿病患者的血糖水平。Metformin is a biguanide oral hypoglycemic agent, which is the most commonly used oral hypoglycemic agent in clinical use.
One of the first-line oral hypoglycemic drugs is used in patients with type 2 diabetes who are not satisfied with simple diet control, especially those with obesity and hyperinsulinemia. Metformin main pass
Intestinal intake, increase insulin sensitivity, increase the utilization of peripheral glucose, and inhibit excessive gluconeogenesis of liver and kidney, and not reduce blood sugar levels in non-diabetic patients.
二甲双胍的副作用主要包括大部分服二甲双胍后会出现消化道反应，如腹泻、恶心、呕吐、腹胀、口腔异味等，长期服用也容易产生胰岛素抵抗，药效降低，常常联合服用多种口服降糖药物，又会产生肝脏、肾脏的药源型损伤。
The side effects of metformin mainly include digestive tract reactions such as diarrhea, nausea, vomiting, bloating, and bad breath. Most of them are prone to insulin resistance and have reduced efficacy. They are often combined with various oral hypoglycemic agents. It will also cause drug-type damage to the liver and kidneys.
发明内容：Summary of the invention:
本发明涉及一种II型糖尿病患者用营养品，在II型糖尿病患者服用二甲双胍后再服用本发明的营养品后，可以克服二甲双胍对人体造成的副作用反应，以解决现有II型糖尿病患者服用二甲双胍对人体造成的副作用的技术问题。The invention relates to a nutrient for a type II diabetes patient, which can overcome the side effect of metformin on the human body after taking the metformin in the type II diabetes patient, and can solve the problem of taking metformin in the existing type II diabetes patient. Technical problems with side effects caused by the human body.
为了解决以上技术问题，本发明采取的技术方案是：In order to solve the above technical problems, the technical solution adopted by the present invention is:
一种II型糖尿病患者用营养品，其特征是，包括以下组分：果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌。A nutrient for type II diabetes patients, which comprises the following components: fruit and vegetable fiber, prebiotics, oat glucan, blueberry extract, bitter gourd extract and probiotics.
所述果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：The proportions of the fruits and vegetables fiber, prebiotics, oat dextran, blueberry extract, bitter gourd extract and probiotics are respectively:
果蔬纤维40%-60%Fruit and vegetable fiber 40%-60%
益生元20%-30%Prebiotics 20%-30%
燕麦葡聚糖5%-15%Oat dextran 5%-15%
蓝莓提取物5%-15%Blueberry extract 5%-15%
苦瓜提取物1%-5%Momordica extract 1%-5%
益生菌1%-5%。Probiotics 1% - 5%.
所述II型糖尿病患者用营养品不再含有其它组分。The type II diabetic patient no longer contains other components with the nutrient.
所述果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：The proportions of the fruits and vegetables fiber, prebiotics, oat dextran, blueberry extract, bitter gourd extract and probiotics are respectively:
果蔬纤维50%Fruit and vegetable fiber 50%
益生元20%Prebiotic 20%
燕麦葡聚糖10%Oat glucan 10%
蓝莓提取物15%Blueberry extract 15%
苦瓜提取物2%Momordica extract 2%
益生菌3%。Probiotics 3%.
在采用了上述技术方案后，由于果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌调节人体肠道菌群平衡，各组分的作用机制和协同机制，可以抵消二甲双胍导致的腹泻、恶心、呕吐、腹胀及口腔异味的消化道反应，解决了现有II型糖尿病患者服用二甲双胍对人体造成的副作用的技术问题。同时还可以增加二甲双胍的疗效，增加二甲双胍的抵御胰岛素抵抗的能力，逐步减少口服二甲双胍的用药量。After adopting the above technical scheme, the mechanism of action and synergistic mechanism of each component can be offset by the balance of fruit and vegetable fiber, prebiotics, oat glucan, blueberry extract, bitter gourd extract and probiotics to regulate the intestinal flora of human body. The digestive tract reaction caused by metformin, nausea, vomiting, bloating and oral odor, solves the technical problem of the side effects of metformin in patients with type 2 diabetes. At the same time, it can also increase the efficacy of metformin, increase the ability of metformin to resist insulin resistance, and gradually reduce the dose of oral metformin.
具体实施方式detailed description
一种II型糖尿病患者用营养品，包括以下组分：果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌。果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：A nutritional supplement for type II diabetes patients, comprising the following components: fruit and vegetable fiber, prebiotics, oat dextran, blueberry extract, bitter gourd extract and probiotics. The proportions of fruit and vegetable fiber, prebiotics, oat dextran, blueberry extract, bitter gourd extract and probiotics are:
果蔬纤维40%-60%Fruit and vegetable fiber 40%-60%
益生元20%-30%Prebiotics 20%-30%
燕麦葡聚糖5%-15%Oat dextran 5%-15%
蓝莓提取物5%-15%Blueberry extract 5%-15%
苦瓜提取物1%-5%Momordica extract 1%-5%
益生菌1%-5%Probiotics 1%-5%
各组分的具体的配比如下表（以总重量为100克为例）：The specific composition of each component is as follows (for example, the total weight is 100 grams):
|
组分 含量 序号Component content number |
果蔬纤维Fruit and vegetable fiber | 益生元Prebiotics | 燕麦葡聚糖Oat glucan | 蓝莓提取物Blueberry extract | 苦瓜提取物Bitter gourd extract | 益生菌Probiotics | 效果effect |
| 实施例1Example 1 | 4040 | 3030 | 1515 | 1010 | 22 | 33 | 一般general |
| 实施例2Example 2 | 5050 | 2020 | 1010 | 1515 | 22 | 33 | 最佳optimal |
| 实施例3Example 3 | 6060 | 2020 | 1010 | 55 | 11 | 44 | 一般general |
| 实施例4Example 4 | 6060 | 2020 | 1010 | 55 | 22 | 33 | 一般general |
| 实施例5Example 5 | 5555 | 2525 | 1010 | 55 | 33 | 22 | 一般general |
| 实施例6Example 6 | 5050 | 3030 | 55 | 1010 | 44 | 11 | 一般general |
| 实施例7Example 7 | 5050 | 3030 | 55 | 1010 | 44 | 11 | 较好better |
| 实施例8Example 8 | 5050 | 2525 | 1010 | 1010 | 22 | 33 | 较好better |
| 实施例9Example 9 | 5555 | 2020 | 1515 | 55 | 33 | 22 | 一般general |
| 实施例10Example 10 | 6060 | 2525 | 55 | 55 | 22 | 33 | 一般general |
| 实施例11Example 11 | 5050 | 3030 | 55 | 1010 | 44 | 11 | 较好better |
| 实施例12Example 12 | 4545 | 2020 | 1515 | 1515 | 44 | 11 | 一般general |
| 实施例13Example 13 | 4545 | 2020 | 1515 | 1010 | 55 | 55 | 一般general |
| 实施例14Example 14 | 4040 | 2525 | 1515 | 1515 | 22 | 33 | 一般general |
| 实施例15Example 15 | 5050 | 3030 | 55 | 55 | 55 | 55 | 较好better |
| 实施例16Example 16 | 5050 | 2020 | 55 | 1010 | 44 | 11 | 较好better |
| 实施例17Example 17 | 5050 | 2525 | 1010 | 1010 | 22 | 33 | 较好better |
| 实施例18Example 18 | 5050 | 3030 | 55 | 55 | 55 | 55 | 较好better |
由于人体口服营养品量有限，尤其是病人，本II型糖尿病患者用营养品不含有其它组分时效果最佳，很明显，由于是营养品，搀入其它对人体无害的组分当然也可以。本发明的营养品，其主要应用于II型糖尿病的辅助治疗，其通过调节人体肠道菌群平衡，可以抵消二甲双胍导致的腹泻、恶心、呕吐、腹胀及口腔异味的消化道反应，还可以增加二甲双胍的疗效，增加二甲双胍的抵御胰岛素抵抗的能力，可以逐步减少口服二甲双胍的用药量。Due to the limited amount of oral nutrition in the human body, especially in patients, this type II diabetes patient has the best effect when it does not contain other components. It is obvious that because it is a nutrient, it is also a component that is harmless to the human body. can. The nutritional product of the invention is mainly applied to the auxiliary treatment of type II diabetes, which can counteract the digestive tract reaction caused by metformin caused by diarrhea, nausea, vomiting, bloating and oral odor by regulating the balance of human intestinal flora, and can also increase The efficacy of metformin, which increases the ability of metformin to resist insulin resistance, can gradually reduce the dose of oral metformin.
本发明涉及的医用营养品通过调节人体肠道菌群平衡，The medical nutrition product of the invention regulates the balance of the human intestinal flora by
1、配方组分的作用机制1. Mechanism of action of formula components
- ·肠道菌群调控机制 ·Intestinal flora regulation mechanism
主要涉及本发明的果蔬纤维、益生元以及益生菌三个成分的作用。其中果蔬纤维和益生元可以共同促进益生菌（含乳酸杆菌和双歧杆菌）的增殖，创造一个益生菌数量快速增加的环境。从而提高益生菌／致病菌的比例，可以直接改善二甲双胍引起的腹泻、恶心、呕吐、腹胀等副作用。It mainly relates to the functions of the three components of the fruit and vegetable fiber, the prebiotic and the probiotic of the present invention. Among them, fruit and vegetable fiber and prebiotics can jointly promote the proliferation of probiotics (including lactobacilli and bifidobacteria), creating an environment in which the number of probiotics increases rapidly. Therefore, increasing the proportion of probiotics/pathogenic bacteria can directly improve side effects such as diarrhea, nausea, vomiting, and bloating caused by metformin.
- ·燕麦葡聚糖 ·Oat dextran
主要通过结肠紧密连接蛋白通路，改善肠黏膜机械屏障和生物屏障的损伤,起到保护肠黏膜屏障的作用。从而降低二甲双胍的副作用。It mainly protects the intestinal mucosal barrier by improving the intestinal barrier mechanical barrier and biological barrier damage through the colon tight junction protein pathway. Thereby reducing the side effects of metformin.
- ·蓝莓提取物作用机制 ·Blueberry extract mechanism
蓝莓提取物只要通过花青素发挥作用，花青素是一种天然抗氧化剂。花青素含有多个酚性羟基，在体内被氧化后释放出H+，竞争性地与自由基及氧化物结合，从而保护脂质不被氧化，阻断自由基链式反应。通过有效清除肠道内有害自由基，降低二甲双胍的副作用。Blueberry extract is a natural antioxidant as long as it acts through anthocyanins. Anthocyanins contain a plurality of phenolic hydroxyl groups, which are oxidized in the body to release H+, competitively bind to free radicals and oxides, thereby protecting lipids from oxidation and blocking free radical chain reactions. Reduces the side effects of metformin by effectively removing harmful free radicals from the gut.
- ·苦瓜提取物作用机制 ·The mechanism of action of bitter gourd extract
苦瓜提取物只要通过苦瓜皂甙发挥作用，苦瓜皂甙主要作用于肠道刷状缘。通过影响α－葡萄糖苷酶，其存在于小肠刷状缘膜的近腔上皮细胞内，主要作用是使淀粉、糊精、麦芽糖和蔗糖等降解为单糖。α－糖苷酶抑制剂是目前研究较多的糖尿病口服降糖药物，对葡萄糖苷酶有高度的亲和性，作用在小肠粘膜刷状缘，可通过延缓碳水化合物在肠道的消化和吸收，抑制餐后血糖水平的升高，同时在一定程度上能降低空腹血糖。The bitter gourd extract acts only through the bitter gourd saponin, and the bitter gourd saponin acts mainly on the intestinal brush border. By affecting α-glucosidase, it is present in the proximal epithelial cells of the brush border membrane of the small intestine, and its main function is to degrade starch, dextrin, maltose and sucrose into monosaccharides. Alpha-glycosidase inhibitors are currently the most studied oral hypoglycemic drugs for diabetes. They have a high affinity for glucosidase and act on the brush border of the small intestine mucosa, which can delay the digestion and absorption of carbohydrates in the intestine. It inhibits the increase of postprandial blood glucose levels, while at the same time reducing the fasting blood glucose to a certain extent.
- ·协同作用机制 ·Synergy mechanism
主要通过本发明涉及的果蔬纤维、益生元和益生菌共同作用，营造一个益生菌可以快速增值，甚至占主导的肠道菌群环境；并且通过本发明涉及的燕麦葡聚糖对肠道黏膜的修复和保护；蓝莓提取物对肠道内有害自由基的清除，以及苦瓜提取物主要于肠道刷状缘，延缓碳水化合物在肠道的消化和吸收，四个不同的作用途径，降低二甲双胍由于对消化道的刺激导致的副作用，从而提高二甲双胍的作用疗效。Mainly through the combination of the fruits and vegetables fibers, prebiotics and probiotics involved in the present invention, to create a probiotic bacteria can quickly increase the value, even dominate the environment of the intestinal flora; and through the oat glucan involved in the present invention on the intestinal mucosa Repair and protection; blueberry extract removes harmful free radicals from the intestines, and bitter gourd extract is mainly in the intestinal brush border, delaying the digestion and absorption of carbohydrates in the intestine, four different pathways of action, reducing metformin due to The side effects caused by the stimulation of the digestive tract, thereby improving the therapeutic effect of metformin.
Claims (4)
- 一种II型糖尿病患者用营养品，其特征是，包括以下组分：果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌。A nutrient for type II diabetes patients, which comprises the following components: fruit and vegetable fiber, prebiotics, oat glucan, blueberry extract, bitter gourd extract and probiotics.
- 如权利要求1所述的II型糖尿病患者用营养品，其特征是，所述果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：The nutrient for type II diabetes patients according to claim 1, wherein the proportion of the fruit and vegetable fiber, the prebiotic, the oat dextran, the blueberry extract, the bitter gourd extract and the probiotics are respectively:果蔬纤维40%-60%Fruit and vegetable fiber 40%-60%益生元20%-30%Prebiotics 20%-30%燕麦葡聚糖5%-15%Oat dextran 5%-15%蓝莓提取物5%-15%Blueberry extract 5%-15%苦瓜提取物1%-5%Momordica extract 1%-5%益生菌1%-5%。Probiotics 1% - 5%.
- 如权利要求1或2所述的II型糖尿病患者用营养品，其特征是，所述II型糖尿病患者用营养品不再含有其它组分。The nutrient for type II diabetes patients according to claim 1 or 2, wherein the type II diabetes patient no longer contains other components with the nutrient.
- 如权利要求3所述的II型糖尿病患者用营养品，其特征是，所述果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：The nutrient for type II diabetes patients according to claim 3, wherein the proportion of the fruit and vegetable fiber, the prebiotic, the oat glucan, the blueberry extract, the bitter gourd extract and the probiotics are respectively:果蔬纤维50%Fruit and vegetable fiber 50%益生元20%Prebiotic 20%燕麦葡聚糖10%Oat glucan 10%蓝莓提取物15%Blueberry extract 15%苦瓜提取物2%Momordica extract 2%益生菌3%。Probiotics 3%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710460014.5 | 2017-06-17 | ||
| CN201710460014.5A CN107307417A (en) | 2017-06-17 | 2017-06-17 | A kind of type 2 diabetes patient's nutriment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018227749A1 true WO2018227749A1 (en) | 2018-12-20 |
Family
ID=60181827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2017/097584 WO2018227749A1 (en) | 2017-06-17 | 2017-08-16 | Nutriment for type 2 diabetes patient |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107307417A (en) |
| WO (1) | WO2018227749A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104489646A (en) * | 2014-11-19 | 2015-04-08 | 李雅君 | Fruit and vegetable probiotic tablet and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520857A (en) * | 2003-01-27 | 2004-08-18 | 永 张 | Diabetes treating bitter gourd traditional Chinese medicine |
| CN102488220A (en) * | 2011-11-28 | 2012-06-13 | 中哈福生物医药科技（上海）有限公司 | Hypoglycemic compound, its preparation method and health food with hypoglycemic function |
| CN102630948A (en) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | High-fiber sugar-free fruit flavored type compound prebiotics and preparation method thereof |
| CN104127594A (en) * | 2014-08-14 | 2014-11-05 | 孙战强 | Phytoextraction composition applied to prevention and control of diabetes |
| CN104187670A (en) * | 2014-09-02 | 2014-12-10 | 高鹏 | Special dietary formula for assisting patients with diabetes in regulating blood sugar |
| CN105661547A (en) * | 2016-01-22 | 2016-06-15 | 湖南营养树科技有限公司 | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement |
| CN105661245A (en) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | Probiotic type fruit and vegetable enzyme solid drink |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
| CN106689959A (en) * | 2017-01-10 | 2017-05-24 | 唐山金鼎盛生物科技有限公司 | Solid beverage for assisting blood glucose regulation |
-
2017
- 2017-06-17 CN CN201710460014.5A patent/CN107307417A/en active Pending
- 2017-08-16 WO PCT/CN2017/097584 patent/WO2018227749A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104489646A (en) * | 2014-11-19 | 2015-04-08 | 李雅君 | Fruit and vegetable probiotic tablet and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| KONG, XIANGQIANG: "Health functions of Anthocyanin in Blueberry (non-official translation)", MODERN AGRICULTURAL SCIENCES AND TECHNOLOGY, no. 15, 10 August 2009 (2009-08-10), pages 130 * |
| SHEN, RUILING ET AL.: "Study progress on the physiological functions of oat-beta-glucan (non-official translation)", FOOD & MACHINERY, vol. 23, no. 6, 18 November 2007 (2007-11-18), pages 126 - 128 * |
| YUAN, ZUHUA ET AL.: "Study progress on the nutrition chemical composition and health functions of Momordica Charantia L. (non-official translation)", HUNAN AGRICULTURAL SCIENCES, no. 5, 30 September 2006 (2006-09-30), pages 48 - 50 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107307417A (en) | 2017-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Odes et al. | A double-blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation | |
| ES2886951T3 (en) | Composition for use in modulating the microbiota | |
| RU2731148C2 (en) | Composition for use in preventing or treating infections/inflammations in the gastrointestinal tract in infants or young children | |
| CN108348536B (en) | Synthetic compositions for treating antibiotic-associated complications | |
| RU2009139658A (en) | PROBIOTICS TO IMPROVE THE INTESTINAL MICROBIOTES | |
| CA2416990A1 (en) | Nutritional composition | |
| US20160166631A1 (en) | Nutraceutical combination for prevention and treatment of type 2 diabetes | |
| RU2005134174A (en) | SYNBIOTIC COMBINATION | |
| Wei et al. | The functional role of sulforaphane in intestinal inflammation: a review | |
| CN103156108B (en) | Fortified food for preventing and treating diabetes mellitus and hypertension diseases | |
| Witaicenis et al. | Dietary polydextrose prevents inflammatory bowel disease in trinitrobenzenesulfonic acid model of rat colitis | |
| AU2004257742A1 (en) | Method for treating irritable bowel syndrome using laxatives | |
| MX2013000670A (en) | Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment. | |
| McRorie Jr et al. | Psyllium: the gel-forming nonfermented isolated fiber that delivers multiple fiber-related health benefits | |
| Vaezi et al. | The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID‐19 patients: A randomized placebo‐controlled trial | |
| Ruan et al. | Encapsulated Bifidobacteria reduced bacterial translocation in rats following hemorrhagic shock and resuscitation | |
| CN114931598A (en) | Gastric soluble sustained-release tablet for preventing and treating helicobacter pylori infection and preparation method thereof | |
| Tian et al. | Early-life galacto-oligosaccharides supplementation alleviates the small intestinal oxidative stress and dysfunction of lipopolysaccharide-challenged suckling piglets | |
| US9713610B2 (en) | Pharmaceutical composition for treating gastro-oesophageal reflux disease | |
| WO2018227749A1 (en) | Nutriment for type 2 diabetes patient | |
| CN111166776A (en) | Formula for eradicating chronic gastritis caused by helicobacter pylori | |
| JP2002226369A (en) | Glutamine-containing oral composition | |
| WO2014165975A1 (en) | Compositions for prevention and/or treatment of gastrointestinal imbalances in digestive disorders | |
| JP3245724U (en) | Composite multilayer structure of composition for improving intestinal inflammation containing Bacillus coagulans BC198 strain | |
| Baobid et al. | Beta-glucan intake with energy and carbohydrate restricted meals: impact on subjective appetite and gastrointestinal appetite hormones in overweight adults |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17913337 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 18.05.2020) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17913337 Country of ref document: EP Kind code of ref document: A1 |